Cargando…

Adjunctive Recombinant Human Plasma Gelsolin for Severe Coronavirus Disease 2019 Pneumonia

BACKGROUND: Excessive inflammation contributes to the morbidity and mortality of severe coronavirus disease 2019 (COVID-19) pneumonia. Recombinant human plasma gelsolin (rhu-pGSN) improves disease outcomes in diverse experimental models of infectious and noninfectious inflammation. METHODS: In a bli...

Descripción completa

Detalles Bibliográficos
Autores principales:	DiNubile, Mark J, Parra, Sandra, Salomó, Antoni Castro, Levinson, Susan L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345409/ https://www.ncbi.nlm.nih.gov/pubmed/35928505 http://dx.doi.org/10.1093/ofid/ofac357

Ejemplares similares

Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia
por: DiNubile, Mark J, et al.
Publicado: (2020)

Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia
por: Yang, Zhiping, et al.
Publicado: (2017)

Plasma gelsolin as a biomarker of inflammation
por: DiNubile, Mark J
Publicado: (2008)

Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza
por: Yang, Zhiping, et al.
Publicado: (2020)

Recombinant human plasma gelsolin (rhu-pGSN) in a patient hospitalized with critical COVID-19 pneumonia
por: Catteeuw, Julie V., et al.
Publicado: (2021)

Association of plasma gelsolin with frailty phenotype and mortality among octogenarian community-dwelling men: a cohort study
por: Strandberg, Timo E., et al.
Publicado: (2022)

Plasma gelsolin levels are associated with diabetes, sex, race, and poverty
por: Noren Hooten, Nicole, et al.
Publicado: (2023)

Low HDL-c levels at admission are associated with greater severity and worse clinical outcomes in patients with COVID-19 disease
por: Parra, Sandra, et al.
Publicado: (2023)

Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019
por: Tziolos, Nikolaos, et al.
Publicado: (2021)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine
por: Allen, Keith B., et al.
Publicado: (2014)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
por: Howe, John A., et al.
Publicado: (2014)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies
por: Squires, Kathleen, et al.
Publicado: (2017)

Clinical Manifestation and Neonatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
por: Xu, Shuang, et al.
Publicado: (2020)

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
por: Kumar, Princy N, et al.
Publicado: (2021)

The actin filament-severing domain of plasma gelsolin
Publicado: (1986)

Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia: A multicenter study
por: Son, Hyo-Ju, et al.
Publicado: (2021)

Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Coronavirus Disease 2019 Severity and Risk of Subsequent Cardiovascular Events
por: Wiemken, Timothy L, et al.
Publicado: (2022)

Measurement of Severe Acute Respiratory Syndrome Coronavirus 2 Antigens in Plasma of Pediatric Patients With Acute Coronavirus Disease 2019 or Multisystem Inflammatory Syndrome in Children Using an Ultrasensitive and Quantitative Immunoassay( )
por: Sigal, George B, et al.
Publicado: (2022)

Differentiating Between 2019 Novel Coronavirus Pneumonia and Influenza Using a Nonspecific Laboratory Marker–Based Dynamic Nomogram
por: Wang, Linghang, et al.
Publicado: (2020)

Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019( )
por: Castanha, Priscila M S, et al.
Publicado: (2022)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

Noninferior Antibiotics: When Is “Not Bad” “Good Enough”?
por: DiNubile, Mark J.
Publicado: (2016)

Plasma gelsolin promotes re-epithelialization
por: Wittmann, J., et al.
Publicado: (2018)

Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2022)

Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Magnus, Maria C, et al.
Publicado: (2022)

Dying at Home Due to Coronavirus Disease 2019
por: Edwards, Jessie K, et al.
Publicado: (2022)

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
por: Olender, Susan A, et al.
Publicado: (2021)

Coronavirus Disease 2019–Associated Invasive Fungal Infection
por: Baddley, John W, et al.
Publicado: (2021)

Pretest Symptom Duration and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain Reaction Predict Coronavirus Disease 2019 Mortality
por: Miller, Emily Happy, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021
por: Couture, Alexia, et al.
Publicado: (2022)

Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate
por: Clancy, Cornelius J, et al.
Publicado: (2022)

Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial
por: Malchair, Pierre, et al.
Publicado: (2023)

Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients
por: Tang, Juanjie, et al.
Publicado: (2021)

Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
por: Khatri, Akshay, et al.
Publicado: (2021)

Coronavirus Disease 2019 Vaccination Is Associated With Reduced Outpatient Antibiotic Prescribing in Older Adults With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2: A Population-Wide Cohort Study
por: MacFadden, Derek R, et al.
Publicado: (2023)

Plasma Gelsolin Levels Decrease in Diabetic State and Increase upon Treatment with F-Actin Depolymerizing Versions of Gelsolin
por: Khatri, Neeraj, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_29f8jdru5ibluefjkd1oikvgc5